Medline Reports Third Quarter and Nine Months 2026 Results
Globe Newswire•04/11/2026•07:30 ET
0
Key Highlights
- ➤Q3 net sales $7.9 billion, up 10.4% year over year
- ➤Q3 Adjusted EBITDA $960 million, up 11.8% year over year
- ➤Nine-month net income fell 28.8% to $696 million, including $316 million in fire losses
- ➤2026 Organic Sales guidance raised to 10.0% to 10.5% from 9.0% to 10.0%
- ➤Board authorized a $1 billion share repurchase program
Expert Statements
Jim Boyle, Chief executive officer of Medline
“Medline delivered another strong quarter, with double-digit net sales growth, reflecting continued momentum across our business. Our commercial execution remains strong, including continued progress toward our annual total new customer signings(4) goal. We are advancing key strategic priorities, including capacity expansion and new technology across our distribution network and progress with our global quality initiatives. We remain focused on serving our customers, advancing our strategic priorities and driving sustainable long-term growth.”
Third quarter net sales of $7.9 billion, an increase of 10.4%
Third quarter Adjusted EBITDA(1) of $1.0 billion, an increase of 11.8%
Get started
Create a free account to read the full story.